Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist
- PMID: 32890594
- DOI: 10.1016/j.jhep.2020.08.014
Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist
Keywords: Liver biopsy; NASH; Pathology reliability.
Conflict of interest statement
Conflict of interest None for this editorial. Dr. Brunt has been a study pathologist for Cymabay, Histoindex, and NGM, a consultant for Alnylam/Regeneron Therapeutics, Arrowhead Pharmaceutical, Perspectum Diagnostics, and a member of the Advisory Board for Pfizer. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.J Hepatol. 2020 Dec;73(6):1322-1332. doi: 10.1016/j.jhep.2020.06.025. Epub 2020 Jun 28. J Hepatol. 2020. PMID: 32610115 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources